Customer Success Story: OKAVA Advances the First Randomized Veterinary GLP-1 Clinical Trial Using Captivate® Electronic Data Capture (EDC)
About the Customer
OKAVA Pharmaceuticals is a clinical-stage veterinary biotech company developing GLP-1 therapies and other transformative treatments for chronic diseases in companion animals. As pet obesity and cardiometabolic disorders continue to rise, OKAVA is working to close a long-standing innovation gap in veterinary medicine through rigorous, data-driven clinical trials.
The Challenge: Executing a Randomized Veterinary Clinical Trial Without Enterprise Burden
Launching MEOW-1, the first fully randomized GLP-1 clinical trial in client-owned cats, required a level of structure comparable to a human Phase 2B study.
OKAVA needed to:
• Deploy enterprise-grade electronic data capture
• Configure randomized study workflows
• Capture cardiometabolic endpoints including insulin and A1C
• Maintain real-time oversight
• Move quickly with a lean operational team
For many early-stage biotech sponsors, traditional EDC software creates friction. Long build timelines, rigid configurations, and high cost structures can delay study launch and strain internal resources.
OKAVA needed an EDC platform that delivered speed, control, and scalability without enterprise-level complexity.
The Solution: Captivate® Electronic Data Capture (EDC) Built for Agile Clinical Trial Teams
"This was our third EDC platform, And this was by far the easiest build. It’s very user-friendly, and the support has been phenomenal. Questions get answered within 30 minutes."
OKAVA selected Captivate® Electronic Data Capture (EDC) to power MEOW-1, enabling the team to design and build its veterinary clinical trial in-house.
With Captivate®, OKAVA was able to:
• Rapidly configure electronic case report forms
• Execute structured randomization workflows
• Monitor data in real time
• Maintain oversight across sites
• Operate efficiently without expanding headcount
By removing unnecessary technical barriers, Captivate allowed OKAVA to focus on clinical execution rather than system management.
For veterinary biotech companies evaluating electronic data capture software, usability and implementation speed can directly impact study timelines. Captivate provided enterprise-grade functionality with startup-level agility.
The Results: Enterprise-Level Trial Execution. Startup-Level Efficiency.
Although MEOW-1 is ongoing, the impact is already clear.
OKAVA has successfully launched a randomized, endpoint-driven veterinary clinical trial that mirrors the structure of human pharmaceutical development, positioning the company at the forefront of GLP-1 research in companion animals.
With Captivate® EDC, OKAVA achieved:
• High-quality, structured data collection
• Real-time operational visibility
• Efficient cross-team collaboration
• Confident execution of a complex randomized study
The trial has also drawn international attention to the growing challenge of pet obesity and the potential for GLP-1 therapies in veterinary medicine.
“If we keep pets leaner and healthier,” Klotsman notes, “that translates into more years with them. And who wouldn’t want another year or two with their dog or cat?”
Looking Ahead: Scaling Veterinary Clinical Innovation with the Right EDC Infrastructure
As OKAVA advances beyond MEOW-1, the company plans to expand research into additional metabolic and chronic disease indications, including feline diabetes and chronic kidney disease. Future studies will require scalable clinical trial infrastructure capable of supporting larger patient populations, expanded endpoints, and multi-site coordination.
For growing veterinary biotech sponsors, selecting the right electronic data capture platform is not just about launching a single study. It is about building a foundation that can scale across development phases, indications, and regulatory pathways.
With Captivate®, OKAVA has established a clinical trial framework designed for long-term growth, operational control, and data integrity.
For sponsors evaluating EDC software for veterinary or companion animal clinical trials, the path forward is clear:
Advanced study design, rapid deployment, and enterprise-grade oversight are achievable without enterprise-level complexity.
